Abstract The coronavirus disease 2019 (COVID-19) pandemic has become a global health
crisis. Considering the recent food and drug administration (FDA) approval of remdesivir as …

Clinical question What is the role of remdesivir in the treatment of severe covid-19? This
guideline was triggered by the ACTT-1 trial published in the New England Journal of …

Background Remdesivir was given UK early-access approval for use in COVID-19 in people
aged 12 years and older on 26th May 2020 on the basis of unmet clinical need. Evidence on …

Despite the wide availability of effective vaccines, COVID-19 continues to be an infectious
disease of global importance. Remdesivir is a broad-spectrum antiviral and was the first US …

Background Effective drug treatments for Covid-19 are needed to decrease morbidity and
mortality for the individual and to alleviate pressure on health care systems. Remdesivir …

Background Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro
and efficacy in animal models of coronavirus disease 2019 (Covid-19). Methods We …

Objectives Evaluation of remdesivir, an RNA polymerase inhibitor, for effectiveness in adults
with COVID-19. Data sources Electronic search for eligible articles of PubMed, Cochrane …

Introduction There is a need to identify effective, safe treatments for COVID-19 (coronavirus
disease) rapidly, given the current, ongoing pandemic. A systematic benefit–risk assessment …

Abstract Background and Objectives Remdesivir is an antiviral agent, which was shown to
be safe and effective in treating early COVID-19, but its favourable impact in hospitalised …

Background We compared the efficacy of the antiviral agent, remdesivir, versus standard-of-
care treatment in adults with severe coronavirus disease 2019 (COVID-19) using data from a …